Martina Porter, MD

Oral JAK1 povorcitinib shows manageable adverse acne and strong responses even after biologic failure, offering an alternative to injections.

Martina Porter, MD, highlights phase 3 data showing povorcitinib boosts hidradenitis suppurativa responses by week 3 and sustains gains to 54 weeks in refractory patients.

In the final episode, the panel pulls together the clinical “bottom line” from the phase 3 povorcitinib data for hidradenitis suppurativa (HS).

In this episode, our panel delves into the safety and tolerability of povorcitinib, specifically addressing the concerns clinicians often face regarding the JAK inhibitor class.

In this episode, the expert dermatologists explore the quality-of-life outcomes from the STOP HS trials, emphasizing that for patients, the biggest wins are often less pain and less drainage, outcomes not fully captured by HiSCR.

This episode features panelists moving beyond HiSCR50 to examine the “depth of response” endpoints—HiSCR75, HiSCR90, and HiSCR100—and what they mean clinically.

In this episode, our experts delve into the primary efficacy results of the STOP HS trials, focusing on HiSCR50 at weeks 12 and 24 and how to interpret those numbers.

In this episode, the panelists explore the baseline characteristics of the STOP HS trials and why they matter for interpreting the results and applying them to practice. They first emphasize the achievement of running a >1,200‑patient, global phase 3 HS program, urging clinicians everywhere to refer patients to clinical trials to keep building robust data.

In this first episode, Dr. Hadar Lev-Tov and Dr. Martina Porter convene for a clinical journal club to discuss the emerging landscape of Hidradenitis Suppurativa (HS) treatment.

Earn CME credit and learn how to optimize a multimodal treatment approach for hidradenitis suppurativa.